Osteoradionecrosis of the jaw in a patient with lymphoma treated with rituximab and concomitant involved field radiation therapy

about

Osteoradionecrosis of the jaw in a patient with lymphoma treated with rituximab and concomitant involved field radiation therapy

Item

http://www.wikidata.org/entity/Q58131159

description

wetenschappelijk artikel

@nl

name

Osteoradionecrosis of the jaw ...... volved field radiation therapy

@en

Osteoradionecrosis of the jaw ...... volved field radiation therapy

@nl

type

Item

label

Osteoradionecrosis of the jaw ...... volved field radiation therapy

@en

Osteoradionecrosis of the jaw ...... volved field radiation therapy

@nl

prefLabel

Osteoradionecrosis of the jaw ...... volved field radiation therapy

@en

Osteoradionecrosis of the jaw ...... volved field radiation therapy

@nl

P1476

Osteoradionecrosis of the jaw ...... volved field radiation therapy

@en

P2093

Ioannis Mantzaris

http://www.w3.org/2001/XMLSchema#string

Jesus D Gonzalez-Lugo

http://www.w3.org/2001/XMLSchema#string

Rafi Kabarriti

http://www.w3.org/2001/XMLSchema#string

P2860

Risk profile for osteoradionecrosis of the mandible in the IMRT era

Potential risk factors for jaw osteoradionecrosis after radiotherapy for head and neck cancer.

Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy.

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.

The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience.

Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy.

4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.

In vitro evaluation of radioprotective and radiosensitizing effects of rituximab.

Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.

Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab.

P304

701-704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.ADRO.2018.05.008

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P698

30370372

http://www.w3.org/2001/XMLSchema#string

P921

patient

P932

6200873

http://www.w3.org/2001/XMLSchema#string